Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis
Open Access
- 12 August 2020
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 10 (1) , 1-20
Abstract
The central role played by cerebrospinal-fluid (CSF) examinations including antineuronal autoantibody (Ab) testing is increasingly recognized in psychiatry. The rationale of this study was to present a multimodally investigated group of patients. In total, 992 patients were analyzed for CSF alterations: 456 patients with schizophreniform and 536 with affective syndromes. Ab measurement included testing for established antineuronal IgG-Abs against intracellular antigens in serum (Yo/Hu/Ri/cv2[CRMP5]/Ma1/Ma2/SOX1/TR[DNER]/Zic4/amphiphysin/GAD65) and for cell surface antigens in the CSF (NMDAR/AMPA-1/2-R/GABA-B-R/LGI1/CASPR2/DPPX). In 30 patients with “red flags” for autoimmune psychosis, “tissue tests” were performed. Additional diagnostics included MRI and EEG analyses. CSF white-blood-cell counts were increased in 4% and IgG indices in 2%; CSF-specific oligoclonal bands were detected in 4%; overall, 8% displayed signs of neuroinflammation. In addition, 18% revealed increased albumin quotients. Antineuronal Abs against intracellular antigens were detected in serum in 0.6%. Antineuronal Abs against established cell surface antigens were detected in serum of 1% and in the CSF of 0.3% (CSF samples were only questionably positive). Abnormal IgG binding in “tissue tests” was detected in serum of 23% and in CSF of 27%. In total, 92% of the Ab-positive patients demonstrated at least one sign of brain involvement in additional diagnostics using CSF, MRI, EEG, and FDG-PET. In summary, CSF basic analyses revealed signs of blood–brain-barrier dysfunction and neuroinflammation in relevant subgroups of patients. Established antineuronal IgG-Abs were rare in serum and even rarer in the CSF. “Tissue tests” revealed frequent occurrences of Ab-binding; therefore, novel antineuronal Abs could play a relevant role in psychiatry.Keywords
This publication has 45 references indexed in Scilit:
- Blood–cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatmentPsychiatry Research, 2014
- Paraneoplastische neurologische Syndrome und AutoimmunenzephalitidenDer Nervenarzt, 2014
- Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective studyThe Lancet Neurology, 2014
- Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrityMolecular Psychiatry, 2013
- Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?European Archives of Psychiatry and Clinical Neuroscience, 2011
- Voltage-Gated Potassium Channel/LGI1 Antibody–Associated Encephalopathy May Cause Brief Psychotic DisorderThe Journal of Clinical Psychiatry, 2011
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- Isolated blood–cerebrospinal fluid barrier dysfunction: prevalence and associated diseasesJournal of Neurology, 2005
- Elevated CSF protein in male patients with depressionBiological Psychiatry, 1990
- Blood-cerebrospinal fluid barrier in schizophrenic patientsEuropean Archives of Psychiatry and Clinical Neuroscience, 1987